ECM
RGLS

Endurant Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Endurant Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-354,721
Closed -$2.45M – 79
2021
Q3 		$2.45M Buy
354,721
+93,954
+36% +$688K 0.56% 39
2021
Q2 		$2.12M Buy
260,767
+23,111
+10% +$258K 0.58% 46
2021
Q1 		$3.71M Buy
+237,656
New +$3.52M 0.97% 37

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Endurant Capital Management's RGLS Position: Q4 2021 in Review

Endurant Capital Management sold out of Regulus Therapeutics (RGLS) in Q4 2021, closing a stake of 354,721 shares — an estimated $2.45M sold.

Endurant Capital Management first reported a position in RGLS in Q1 2021 and held it in 3 quarters. The position peaked at $3.71M in Q1 2021. 37 funds tracked by Wall St. Rank hold RGLS as of Q4 2021.

  • Endurant Capital Management reported no remaining Regulus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Endurant Capital Management sold 354,721 Regulus Therapeutics shares in Q4 2021, an estimated $2.45M.
  • Endurant Capital Management first reported a position in Regulus Therapeutics in Q1 2021 and held it in 3 quarters.
  • Endurant Capital Management's Regulus Therapeutics position peaked at $3.71M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2021.

Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.